FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2546924501> ?p ?o ?g. }

• W2546924501 endingPage "939" @default.
• W2546924501 startingPage "939" @default.
• W2546924501 abstract "Background: The oral vasopressin-2 receptor antagonist tolvaptan causes aquaresis in patients with volume overload, which could potentially facilitate decongestion and improve the clinical course of patients with acute heart failure (AHF). Objectives: To address the role of the acute use of tolvaptan to improve symptoms of congestion in AHF, we conducted the Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure Study (TACTICS-HF, NCT01644331). Methods: TACTICS-HF randomized patients within 24 hours of presentation with AHF and volume overload in a prospective, double blind, placebo-controlled trial. Patients were eligible regardless of ejection fraction. Eligible patients were randomized to either 30 mg of tolvaptan or placebo given at 0, 24, and 48 hours, with a fixed dose furosemide regimen as background therapy. The primary endpoint was the proportion of patients with at least moderate improvement in dyspnea by 7-point Likert scale at both 8 and 24 hours and without the need for rescue therapy or death within 24 hours. Secondary endpoints included symptom improvement, changes in renal function, and clinical events. Results: A total of 257 patients were randomized. Dyspnea relief by Likert scale was similar between tolvaptan and placebo at 8 hours (25% moderately or markedly improved for tolvaptan vs. 28% for placebo, P = .59) and at 24 hours (50% moderately or markedly improved for tolvaptan vs. 47% for placebo, P = .80) (Fig. 1). Need for rescue therapy was also similar at 24 hours (21% for tolvaptan, 18% for placebo, P = .57). The proportion of patients defined as responders at 24 hours (the primary study endpoint) was 16% in tolvaptan and 20% in placebo (P = .32). Tolvaptan did result in greater weight loss and net fluid loss, as well as trends towards improved dyspnea relief, less worsening heart failure, and a greater proportion of patients classified as responders at 48 and 72 hours. Tolvaptan treated patients were more likely to experience worsening renal function during treatment, although changes in renal function were generally modest. There were no differences in in-hospital or post-discharge clinical outcomes. Conclusions: In patients hospitalized with AHF, dyspnea, and congestion, the addition of tolvaptan to a standardized furosemide regimen improved weight loss and fluid loss but did not improve the proportion of patients classified as responders at 24 hours." @default.
• W2546924501 created "2016-11-11" @default.
• W2546924501 creator A5011361266 @default.
• W2546924501 creator A5015595507 @default.
• W2546924501 creator A5022076272 @default.
• W2546924501 creator A5033898505 @default.
• W2546924501 creator A5036509904 @default.
• W2546924501 creator A5037713323 @default.
• W2546924501 creator A5041547416 @default.
• W2546924501 creator A5042034622 @default.
• W2546924501 creator A5046957208 @default.
• W2546924501 creator A5058444528 @default.
• W2546924501 creator A5068642565 @default.
• W2546924501 creator A5069065466 @default.
• W2546924501 creator A5070155924 @default.
• W2546924501 creator A5089838429 @default.
• W2546924501 date "2016-11-01" @default.
• W2546924501 modified "2023-09-25" @default.
• W2546924501 title "The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure" @default.
• W2546924501 doi "https://doi.org/10.1016/j.cardfail.2016.09.010" @default.
• W2546924501 hasPublicationYear "2016" @default.
• W2546924501 type Work @default.
• W2546924501 sameAs 2546924501 @default.
• W2546924501 citedByCount "0" @default.
• W2546924501 crossrefType "journal-article" @default.
• W2546924501 hasAuthorship W2546924501A5011361266 @default.
• W2546924501 hasAuthorship W2546924501A5015595507 @default.
• W2546924501 hasAuthorship W2546924501A5022076272 @default.
• W2546924501 hasAuthorship W2546924501A5033898505 @default.
• W2546924501 hasAuthorship W2546924501A5036509904 @default.
• W2546924501 hasAuthorship W2546924501A5037713323 @default.
• W2546924501 hasAuthorship W2546924501A5041547416 @default.
• W2546924501 hasAuthorship W2546924501A5042034622 @default.
• W2546924501 hasAuthorship W2546924501A5046957208 @default.
• W2546924501 hasAuthorship W2546924501A5058444528 @default.
• W2546924501 hasAuthorship W2546924501A5068642565 @default.
• W2546924501 hasAuthorship W2546924501A5069065466 @default.
• W2546924501 hasAuthorship W2546924501A5070155924 @default.
• W2546924501 hasAuthorship W2546924501A5089838429 @default.
• W2546924501 hasConcept C126322002 @default.
• W2546924501 hasConcept C142724271 @default.
• W2546924501 hasConcept C164705383 @default.
• W2546924501 hasConcept C168563851 @default.
• W2546924501 hasConcept C203092338 @default.
• W2546924501 hasConcept C204787440 @default.
• W2546924501 hasConcept C27081682 @default.
• W2546924501 hasConcept C2777955127 @default.
• W2546924501 hasConcept C2778198053 @default.
• W2546924501 hasConcept C2780615674 @default.
• W2546924501 hasConcept C2781413609 @default.
• W2546924501 hasConcept C71924100 @default.
• W2546924501 hasConcept C78085059 @default.
• W2546924501 hasConceptScore W2546924501C126322002 @default.
• W2546924501 hasConceptScore W2546924501C142724271 @default.
• W2546924501 hasConceptScore W2546924501C164705383 @default.
• W2546924501 hasConceptScore W2546924501C168563851 @default.
• W2546924501 hasConceptScore W2546924501C203092338 @default.
• W2546924501 hasConceptScore W2546924501C204787440 @default.
• W2546924501 hasConceptScore W2546924501C27081682 @default.
• W2546924501 hasConceptScore W2546924501C2777955127 @default.
• W2546924501 hasConceptScore W2546924501C2778198053 @default.
• W2546924501 hasConceptScore W2546924501C2780615674 @default.
• W2546924501 hasConceptScore W2546924501C2781413609 @default.
• W2546924501 hasConceptScore W2546924501C71924100 @default.
• W2546924501 hasConceptScore W2546924501C78085059 @default.
• W2546924501 hasIssue "11" @default.
• W2546924501 hasLocation W25469245011 @default.
• W2546924501 hasOpenAccess W2546924501 @default.
• W2546924501 hasPrimaryLocation W25469245011 @default.
• W2546924501 hasRelatedWork W2355594703 @default.
• W2546924501 hasRelatedWork W2507208939 @default.
• W2546924501 hasRelatedWork W2925176333 @default.
• W2546924501 hasRelatedWork W3013207865 @default.
• W2546924501 hasRelatedWork W3033076790 @default.
• W2546924501 hasRelatedWork W3034260459 @default.
• W2546924501 hasRelatedWork W3118940809 @default.
• W2546924501 hasRelatedWork W3155674270 @default.
• W2546924501 hasRelatedWork W3159149223 @default.
• W2546924501 hasRelatedWork W3187572025 @default.
• W2546924501 hasVolume "22" @default.
• W2546924501 isParatext "false" @default.
• W2546924501 isRetracted "false" @default.
• W2546924501 magId "2546924501" @default.
• W2546924501 workType "article" @default.